Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Gulf International Bank UK Ltd

Gulf International Bank UK Ltd reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 1.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 19,223 shares of the medical equipment provider’s stock after selling 198 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Hologic were worth $1,385,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in HOLX. General Partner Inc. acquired a new position in shares of Hologic in the 4th quarter worth approximately $26,000. Groupama Asset Managment lifted its holdings in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC lifted its holdings in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 261 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Finally, Covestor Ltd lifted its holdings in shares of Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 133 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.88% of the company’s stock.

Hologic Trading Up 0.3 %

Shares of Hologic stock opened at $63.38 on Friday. The company has a fifty day simple moving average of $69.16 and a 200-day simple moving average of $75.94. Hologic, Inc. has a 12-month low of $62.69 and a 12-month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $14.22 billion, a price-to-earnings ratio of 19.99, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research note on Monday, February 3rd. UBS Group upped their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Stephens reaffirmed an “overweight” rating and set a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Finally, Raymond James reaffirmed an “outperform” rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Ten research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Hologic has an average rating of “Moderate Buy” and an average price target of $85.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.